Lataa...
Leflunomide Suppresses the Growth of LKB1-inactivated Tumors in the Immune-Competent Host and Attenuates Distant Cancer Metastasis
LKB1-inactivated tumors are vulnerable to the disruption of pyrimidine metabolism, and leflunomide emerges as a therapeutic candidate because its active metabolite, A77–1726, inhibits dihydroorotate dehydrogenase, which is essential for de novo pyrimidine biosynthesis. However, it is unclear whether...
Tallennettuna:
| Julkaisussa: | Mol Cancer Ther |
|---|---|
| Päätekijät: | , , , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7867620/ https://ncbi.nlm.nih.gov/pubmed/33293343 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-20-0567 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|